Log in

NASDAQ:EOLSEvolus Stock Price, Forecast & News

$3.51
+0.09 (+2.63 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.31
Now: $3.51
$3.54
50-Day Range
$3.03
MA: $4.12
$5.78
52-Week Range
$3.00
Now: $3.51
$19.00
Volume333,795 shs
Average Volume869,728 shs
Market Capitalization$118.39 million
P/E RatioN/A
Dividend YieldN/A
Beta2.85
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California. Evolus, Inc. is a subsidiary of ALPHAEON Corporation.
Read More
Evolus logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.54 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EOLS
CUSIPN/A
Phone949-284-4555

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$34.92 million
Book Value$2.38 per share

Profitability

Net Income$-90,030,000.00
Net Margins-217.51%

Miscellaneous

Employees70
Market Cap$118.39 million
Next Earnings Date8/10/2020 (Confirmed)
OptionableOptionable
$3.51
+0.09 (+2.63 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EOLS News and Ratings via Email

Sign-up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Evolus (NASDAQ:EOLS) Frequently Asked Questions

How has Evolus' stock been impacted by COVID-19 (Coronavirus)?

Evolus' stock was trading at $5.91 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EOLS shares have decreased by 40.6% and is now trading at $3.51.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Evolus?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Evolus
.

When is Evolus' next earnings date?

Evolus is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Evolus
.

How can I listen to Evolus' earnings call?

Evolus will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Evolus' earnings last quarter?

Evolus Inc (NASDAQ:EOLS) posted its quarterly earnings results on Monday, May, 11th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.72) by $0.03. The business earned $10.50 million during the quarter, compared to analysts' expectations of $16.91 million. Evolus had a negative return on equity of 197.30% and a negative net margin of 217.51%.
View Evolus' earnings history
.

What price target have analysts set for EOLS?

8 equities research analysts have issued twelve-month target prices for Evolus' shares. Their forecasts range from $3.00 to $30.00. On average, they expect Evolus' share price to reach $11.88 in the next year. This suggests a possible upside of 238.3% from the stock's current price.
View analysts' price targets for Evolus
.

Has Evolus been receiving favorable news coverage?

Media stories about EOLS stock have trended very positive this week, InfoTrie reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Evolus earned a news sentiment score of 4.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about Evolus
.

Who are some of Evolus' key competitors?

What other stocks do shareholders of Evolus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), Advanced Micro Devices (AMD), Revance Therapeutics (RVNC), Camtek (CAMT), Plug Power (PLUG), Micron Technology (MU), Canopy Growth (CGC), Tandem Diabetes Care (TNDM), Calithera Biosciences (CALA) and JD.Com (JD).

Who are Evolus' key executives?

Evolus' management team includes the following people:
  • Mr. David Moatazedi, Pres, CEO & Director (Age 41)
  • Ms. Lauren P. Silvernail, CFO & Exec. VP of Corp. Devel. (Age 60)
  • Mr. Michael Mazen Jafar, Chief Marketing Officer (Age 38)
  • Mr. Alejandro Sabad, VP of Operations
  • Mr. Ashwin K. Agarwal, VP of Fin., Investor Relations & Treasury

When did Evolus IPO?

(EOLS) raised $65 million in an initial public offering (IPO) on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

What is Evolus' stock symbol?

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Who are Evolus' major shareholders?

Evolus' stock is owned by a variety of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.21%) and UBS Group AG (0.19%). Company insiders that own Evolus stock include Corp Alphaeon, David N Gill, Kristine Romine, Lauren P Silvernail, Michael M Jafar, Rui Avelar, Simone Blank and Vikram Malik.
View institutional ownership trends for Evolus
.

Which major investors are buying Evolus stock?

EOLS stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC, and UBS Group AG. Company insiders that have bought Evolus stock in the last two years include David N Gill, Kristine Romine, Michael M Jafar, Simone Blank, and Vikram Malik.
View insider buying and selling activity for Evolus
.

How do I buy shares of Evolus?

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Evolus' stock price today?

One share of EOLS stock can currently be purchased for approximately $3.51.

How big of a company is Evolus?

Evolus has a market capitalization of $118.39 million and generates $34.92 million in revenue each year. The company earns $-90,030,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Evolus employs 70 workers across the globe.

What is Evolus' official website?

The official website for Evolus is www.evolus.com.

How can I contact Evolus?

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected]

This page was last updated on 8/8/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.